peutic Chemical (ATC) code [4] , and quantity purchased as defined daily doses (DDDs; proxy for number of days treated). We extracted information on all AD purchases (ATC code N06A) from 2 years before to 2 years after the index date and used the dispensation date as the start of AD use, projecting the end date with total DDDs dispensed and combining consecutive and overlapping periods of medication as earlier [5] . The 4 years were divided into 16 consecutive 3-month periods (8 before and 8 after death), each with a dichotomous measure of AD use (at least 1 day of treatment).
Baseline characteristics were drawn from the survey before bereavement (in 1997/1998, 2000/2002, or 2004/2005 ). This included: self-rated health (SRH), classified as suboptimal (average/ worse) or optimal (good/very good health); high distress, identified with a cut-off score of 4 in the 12-item General Health Questionnaire [6] ; high anxiety, categorized by a mean score in the highest quartile of the short Trait Anxiety Inventory [7] ; and sleeping problems, reported for at least 2-4 nights a week in the Jenkins Scale [8] . Risk behaviours included heavy alcohol use, with a cutoff of 288 g of absolute ethanol/week for men and 192 g/week for women [9] , current smoking, and physical inactivity (< 2 metabolic equivalents of task-hours/day). Further covariates included participants' age, sex, education (basic/intermediate or high), and presence of chronic conditions including diabetes, rheumatoid arthritis, asthma, or coronary heart disease (acquired from the National Drug Reimbursement Register) or cancer (from the Finnish Cancer Registry).
Trajectory or latent class growth analysis [10] was applied to study patterns of dichotomous AD use over the 16 three-month periods from before to after bereavement, using the expectation and maximization algorithm to model parameter estimates and Bayesian information criteria to select the optimal number of trajectories. For both bereavement groups, 3 trajectories of AD use were identified ( Fig. 1) : "low prevalence" for no use or persistently low use before and after bereavement; "increasing prevalence" for increased use from before to after; and "high prevalence" for persistently high use before and after. Among parentally bereaved subjects, 10% belonged to increasing and 7% to high prevalence, while among child/spousally bereaved individuals, 11% belonged to increasing and 6% to high prevalence. Within the increasing prevalence trajectories, the average number of annual treatment days rose from 244 before to 260 after parental loss, and from 213 before to 257 after child/spousal loss. For high prevalence, the average annual treatment length remained relatively unchanged, at 314 days before and 319 after parental loss, and 325 before and 314 after child/spousal loss.
Baseline characteristics of the sample are given in online supplements (see www.karger.com/doi/10.1159/000489267 for all online suppl. material). Multinomial logistic regression analysis was used to examine potential determinants of these trajectories, adjusting for age and sex, with low prevalence trajectory groups as Death in the family has been shown to influence the health of bereaved relatives [1] . Psychological symptoms caused by bereavement may be linked to the use of psychotropic medications such as antidepressants (AD), yet evidence on AD use patterns around bereavement is sparse [2] . The aim of this study is to describe trajectories of AD use around parental, child, and spousal bereavement, and to examine whether these trajectories vary as function of individual risk factors preceding bereavement.
Data were drawn from linked records of national health registers and repeat surveys in a prospective cohort study of Finnish municipal service personnel [3] . The final study population included 2,040 participants reporting the death of at least 1 family member, with a complete history of AD prescriptions from 2 years before to 2 years after bereavement. Compared to the entire cohort, our study population was older and more likely to be female, with similar levels of education.
Occurrence and timing of death of a parent, child, or spouse within the preceding 12 months were measured from a list of 16 life events [3] . Parental deaths were treated as one group (n = 1,754). Due to few events, child and spousal deaths were combined into another (n = 293). Child/spousal loss was measured in all (Fig. 1) . Observations were weighted with the posterior probability of belonging to the chosen trajectory.
For parentally bereaved subjects, belonging to the increasing prevalence trajectory was predicted by heavy alcohol use, high distress, high anxiety, and sleeping problems before loss. High prevalence was predicted by suboptimal SRH, physical inactivity, high distress, high anxiety, and sleeping problems. For child/spousal loss, increasing prevalence was observed among those with suboptimal SRH, high anxiety, and sleeping problems before loss. Along with heavy alcohol use, physical inactivity, and high distress, these factors were also associated with high prevalence.
All associations remained significant after further adjustment for education and chronic conditions, with the exception of heavy alcohol use for child/spousal loss (online supplements).
In conclusion, we found similarly grouped trajectories in both cohorts. Prior health risks predicted the occurrence of increasing and high AD use trajectories over low trajectories. Despite our use of reliable, high-coverage registers, our study had some limitations. We were unable to stratify our analyses by cause of death or by specific psychiatric diagnosis, which could have revealed altered trajectories of AD use. In lieu of actual dosages, our dichotomous measure of AD purchases may have overestimated the severity of grief. Finally, it is possible that AD use around bereavement may vary by international treatment practices and should thus be explored in differing contexts. Age-and sex-adjusted odds ratios (OR) with 95% confidence intervals (CI) estimated from multinomial logistic regression models using the trajectory of low AD use as a reference group. Information about predictors was drawn from national health registers and responses to an earlier survey before the death of a family member. 
